2025 annual financial data
Halozyme Therapeutics 2025 Operating cash flow growth
Direct answer
Operating cash flow growth was 36.01%.
Operating income was 816,293,000 USD and net income was 316,889,000 USD.
Operating cash flow was 651,558,000 USD.
Get free Halozyme Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 1,396,611,000 USD
- Operating income
- 816,293,000 USD
- Net income
- 316,889,000 USD
- Operating cash flow
- 651,558,000 USD